Drug Search Results
More Filters [+]

Blonanserin

Alternative Names: blonanserin, DSP-5423P, DSP-5423, DSP5423, DSP 5423
Latest Update: 2023-10-06
Latest Update Note: PubMed Publication

Product Description

Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20030420/)

Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist,D3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Japan | Korea

Approved Indications: None

Known Adverse Events: None

Company: Sumitomo Dainippon Pharma Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Blonanserin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DSPCLON-002

P4

Recruiting

Schizophrenia

2024-07-31

CTR20222736

N/A

Completed

Schizophrenia

2022-12-07

CTR20221635

N/A

Completed

Schizophrenia

2022-08-08

CTR20212449

N/A

Completed

Schizophrenia

2021-12-17

Recent News Events